[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Perceive Biotherapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100522810",false,"NCT06087458","Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration","Phase 1\u002F2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration","JOURNEY","Inclusion Criteria:\n\n* Are ≥60 years of age at the time of consent.\n* Are willing and able to understand and provide written informed consent.\n* Are willing and able to return for scheduled treatment and follow-up examinations.\n* Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.\n* Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.\n* Absence of signs of non-exudative MNV.\n* Additional Ocular Inclusion Criteria for both eyes.\n* Meet certain genotype criteria for risk of AMD.\n\nExclusion Criteria:\n\n* Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.\n* Additional Systemic, Ocular, and Genetic Exclusion Criteria.","ALL","60 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.",[27,28,29],"Age-Related Macular Degeneration","Geographic Atrophy","Non-neovascular AMD","RECRUITING","2025-10-13",{"date":33,"type":34},"2025-10-15","ACTUAL",{"date":36,"type":34},"2023-06-21",{"date":38,"type":20},"2028-03",{"name":40,"class":41},"Perceive Biotherapeutics, Inc.","INDUSTRY",11,""]